Single molecule sequencing method
By fixing the nucleic acid template-primer complex on solid phase carriers and polymerization and imaging using nucleotides carrying different optical detection markers, the problems of high sequencing error rate and limited read length in single-molecular sequencing are solved, achieving high Quality and efficient sequencing.
Patent Information
- Application Number
- CN202310632148.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In single-molecular sequencing technology, the sequencing error rate is high and the read length is limited, which affects the sequencing quality and efficiency.
Using a single molecule sequencing method, the nucleic acid template-primer complex is fixed on a solid phase carrier, the polymerization reaction is performed using nucleotides carrying different optical detection marks, the optical signal is excited for imaging, the label is cleared and the process is repeated, and the nucleic acid is realized. Sequence determination. The method includes providing a solid phase carrier, performing polymerization, imaging, clearing optical detection marks and repeating steps to reduce sequencing error rates and improve read length.
It significantly reduces the sequencing error rate, improves the sequencing quality and efficiency, and achieves a longer sequencing read length and a shorter sequencing time.
Smart Images

Figure BDA0004260836120000021 
Figure BDA0004260836120000071 
Figure BDA0004260836120000086
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a single molecule sequencing method. Background Art
[0002] Compared with the second-generation high-throughput sequencing (NGS), single-molecule sequencing directly sequences the nucleic acid molecules to be tested after being fixed with labels on the surface of a solid phase carrier. There is no need to perform PCR amplification on the nucleic acid molecules to be tested, thereby simplifying the construction process of the sequencing library and avoiding errors caused by nucleic acid molecule amplification.
[0003] In the process of single-molecule sequencing, according to the number of nucleotides or their analogs added in each polymerization reaction, single-molecule sequencing can be divided into monochrome sequencing and multi-color sequencing, among which multi-color sequencing can be divided into dual-color sequencing and four-color sequencing. For monochrome sequencing, four single-base extensions are performed respectively by sequentially adding 4 optically detectable labeled nucleotides (G, A, T, C), and in each extension reaction, the signal generated by the optically detectable label of a certain / some visual field is collected, and the type of nucleotide introduced at the site is determined by the signal generated by each site; then, the optically detectable label is removed and the next / round reaction is performed. In this way, it is repeated multiple times or multiple rounds to obtain a group of signal images at different times (each / round reaction) of the corresponding same visual field, and then the information of the group of images is superimposed in the order of the reaction to determine the sequence of the nucleic acid molecule to be tested. Unlike monochrome sequencing, multi-color sequencing adds multiple nucleotides such as two or four at the same time during each single base extension, that is, each single base extension realizes the introduction of at least two nucleotides. Taking dual-color sequencing as an example, each base extension can complete the introduction of two nucleotides, and a round of sequencing can be completed by two base extensions. It can be seen that compared with single-color sequencing, the overall sequencing time of multi-color sequencing can be shortened, but the sequencing read length and sequencing error rate still have limitations. Summary of the invention
[0004] In view of this, the present invention provides a single molecule sequencing method. The single molecule sequencing method provided by the present invention is conducive to reducing the sequencing error rate, improving the sequencing quality, having a longer sequencing read length, and shortening the sequencing time.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides a single molecule sequencing method, comprising the following steps:
[0007] (i) providing a solid phase carrier, wherein the solid phase carrier comprises a plurality of sites, each of which is fixed with a nucleic acid template-primer complex;
[0008] (ii) binding four nucleotides or their analogs carrying different optical detection labels to the nucleic acid template-primer complex through a polymerization reaction to achieve single base extension and obtain an extension product;
[0009] (iii) exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image;
[0010] (iv) removing the optical detection label on the extension product;
[0011] (v) replacing the nucleic acid template-primer complex with the extension product from which the optically detectable label has been cleaved, and repeating the above steps (ii) to (iv) one or more times to determine the template nucleic acid sequence.
[0012] In some embodiments of the present invention, a mixture solution of two or four nucleotides or their analogs carrying different optically detectable labels is contacted with the nucleic acid template-primer complex to allow the nucleotides or their analogs to bind to the nucleic acid template-primer complex.
[0013] In some embodiments of the present invention, the final concentrations of the four nucleotides in the above sequencing method are 125 nmol / L to 1000 nmol / L, respectively.
[0014] In some embodiments of the present invention, the general formula of the nucleotide or its analogue in the above sequencing method is as shown in Formula 1:
[0015]
[0016] Wherein, B is a base or its analogue, L1 and L2 are each independently a covalent bond or a covalent linking group, R1 is -OH or a phosphate group, R2 is H or a chemically cleavable group, R3 is H or -OR5, R5 is H or a chemically cleavable group, and R4 contains the optical detection label.
[0017] In some embodiments of the present invention, in the above sequencing method, B is selected from adenine or its analog, guanine or its analog, cytosine or its analog, thymine or its analog or uracil or its analog.
[0018] In some embodiments of the present invention, in step (ii) of the above sequencing method, B is selected from adenine or its analogs, cytosine or its analogs, thymine or its analogs or uracil or its analogs, and the final concentration of the nucleotide or its analogs is 500nmol / L to 1000nmol / L; B is guanine or its analogs, and the final concentration of the nucleotide or its analogs is 125nmol / L to 500nmol / L.
[0019] In some embodiments of the present invention, in the above sequencing method, different nucleotides or their analogs carry different optical detection labels.
[0020] In some embodiments of the present invention, in the above sequencing method, the optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye or phycoerythrin.
[0021] In some embodiments of the present invention, in the above-mentioned sequencing method, when the nucleotide or its analog is an adenine nucleotide or its analog, the optical detection marker of the nucleotide or its analog is the Atto532; when the nucleotide or its analog is a guanine nucleotide or its analog, the optical detection marker of the nucleotide or its analog is the CY5; when the nucleotide or its analog is a cytosine nucleotide or its analog, the optical detection marker of the nucleotide or its analog is the IF700; when the nucleotide or its analog is a thymine nucleotide or its analog, the optical detection marker of the nucleotide or its analog is the ROX.
[0022] In some embodiments of the present invention, in the above sequencing method, in step (ii), a polymerase is used to bind four nucleotides or their analogs carrying optical detection labels to the nucleic acid template-primer complex to achieve single base extension; wherein the polymerase is a DNA polymerase and / or an RNA polymerase, and the final concentration of the polymerase is 0.005 mg / mL to 0.02 mg / mL.
[0023] In some embodiments of the present invention, in the above sequencing method, the enzyme includes: one or more of 9°N enzyme, Pfu, KOD1 and MMS2.
[0024] In some embodiments of the present invention, in the above sequencing method, in step (ii), the polymerization reaction is carried out at a pH of 8.0 to 9.0.
[0025] In some embodiments of the present invention, the optical detection label is linked to the nucleotide or its analog via a chemically cleavable group, and in step (iv), the removal of the optical detection label on the extension product is achieved using an excision reagent, which includes an organic phosphine and a buffer.
[0026] In some embodiments of the present invention, in the above sequencing method, in step (iv), removing the optical detection label on the extension product is performed at a pH value of 8.0 to 10.5 and a temperature of 39° C. to 65° C.
[0027] In some embodiments of the present invention, in the above sequencing method, the concentration of the organic phosphine is 10 mmol / L to 100 mmol / L; and / or the concentration of the buffer is 0.01 mol / L to 2 mol / L.
[0028] In some embodiments of the present invention, in the above sequencing method, the organic phosphine is selected from tris(3-hydroxypropyl)phosphine, tris(2-carboxyethyl)phosphine, trishydroxymethylphosphine, triphenylphosphine, tris(2-hydroxyethyl)phosphine.
[0029] In some embodiments of the present invention, in step (iii), exciting the optical detection label to generate an optical signal comprises exposing the solid phase carrier to light, wherein the exposure time is 100 ms to 400 ms.
[0030] In some embodiments of the present invention, in the above sequencing method, the optical detection label includes a first optical detection label and a second optical detection label, and the excitation wavelengths of the first optical detection label and the second optical detection label differ by at least 50 nm.
[0031] In some embodiments of the present invention, in the above sequencing method, the first optical detection label is a red light excitable fluorescent group, and the exposure time of the red light excitation group is 100ms to 400ms; the second optical detection label is a green light excitable fluorescent group, and the exposure time of the green light excitation group is 50ms to 100ms.
[0032] The sequencing method provided by the present invention has a lower sequencing error rate, helps to improve sequencing quality, and shortens sequencing time. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0034] Figure 1 The brightness result diagram of dCTP-N3-IF700 and dGTP-N3-CY5 obtained at different exposure times using a 640nm laser provided in the embodiments of the present application;
[0035] Figure 2 A comparison diagram of the C fluorescence image obtained by single-color sequencing and the GC fluorescence image obtained by multi-color sequencing provided in the embodiments of the present application;
[0036] Figure 3 This is a graph showing the effect of different exposure times on the 40-cycle read length distribution provided in the embodiments of the present application;
[0037] Figure 4A result diagram showing the effect of different exposure times on the 50-cycle read length distribution provided in the embodiment of the present application;
[0038] Figure 5 This is a statistical graph of base excision efficiency of four-color sequencing under different concentrations of THPP treatment provided in the examples of the present application;
[0039] Figure 6 This is a statistical graph of base excision efficiency of four-color sequencing using Tris buffer of different concentrations provided in the examples of the present application;
[0040] Figure 7 A statistical graph of base excision efficiency of four-color sequencing under different pH conditions provided in the examples of the present application;
[0041] Figure 8 A statistical graph of base excision efficiency of four-color sequencing under different temperature reactions provided in the embodiments of the present application;
[0042] Fig. 9 A 50-cycle sequencing read length distribution diagram provided in the embodiment of the present application;
[0043] Fig.10 The error rate distribution of 50-cycle four-color sequencing provided in the embodiment of the present application. DETAILED DESCRIPTION
[0044] The invention discloses a single molecule sequencing method.
[0045] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.
[0046] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.
[0047] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.
[0048] The use of any and all examples or exemplary language such as "for example" or "including" herein is only used to better illustrate the present invention and is not used to limit the scope of the present invention. Any language in this specification should not be interpreted as indicating that any unclaimed element is essential to the practice of the present invention.
[0049] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.
[0050] The terms "first", "second", "third", and "fourth" are used only for descriptive purposes to distinguish purposes such as positions, objects, etc. from each other, and should not be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. For example, without departing from the scope of the embodiments of the present application, "first" and "second" can be interchangeable, such as the first site can also be called the second site, and correspondingly, the second site is called the first site. Thus, features defined as "first", "second", "third", and "fourth" may explicitly or implicitly include one or more of the features.
[0051] The term "sequencing" can also be referred to as "nucleic acid sequencing" or "gene sequencing". The three expressions are interchangeable and all refer to the determination of the type and arrangement order of bases or nucleotides (including nucleotide analogs) in nucleic acid molecules. The so-called sequencing includes the process of binding nucleotides to templates and collecting corresponding signals emitted by nucleotides (including analogs). The so-called sequencing includes synthesis sequencing (sequencing by synthesis, SBS) and / or ligation sequencing (sequencing by ligation, SBL), including DNA sequencing and / or RNA sequencing.
[0052] Sequencing generally includes multiple rounds to achieve the process of determining the types and arrangement order of multiple bases or nucleotides on the nucleic acid template. The present application embodiment refers to each round of "the process of determining the types and arrangement order of multiple bases or nucleotides on the nucleic acid template" as "one round of sequencing". "One round of sequencing" (cycle) is also called "sequencing round", which can be defined as a base extension of four nucleotides / bases. In other words, "one round of sequencing" can be defined as the determination of the type of base or nucleotide at any specified position on the template. For sequencing platforms that realize sequencing based on polymerization or ligation reactions, one round of sequencing includes realizing that four nucleotides (including nucleotide analogs) are bound to the so-called nucleic acid template by base complementation, and the corresponding signal emitted is collected. Among them, for platforms that realize sequencing based on polymerization reactions, the reaction system includes reaction substrate nucleotides, polymerases and nucleic acid templates, and a sequence (sequencing primer) is combined with the nucleic acid template. Based on the base pairing principle and the polymerization reaction principle, the added reaction substrate nucleotides are connected to the sequencing primers under the catalysis of the polymerase to realize the binding of the nucleotides to the specific position of the nucleic acid template. Generally, one round of sequencing may include one or more base extensions (repeat). For example, four nucleotides are added to the reaction system in sequence, and base extensions and corresponding reaction signals are collected respectively, and one round of sequencing includes four base extensions. For another example, any combination of the four nucleotides is added to the reaction system, such as two-by-two combinations or one-by-three combinations, and base extensions and corresponding reaction signals are collected respectively for two combinations, and one round of sequencing includes two base extensions. For another example, the four nucleotides are added to the reaction system at the same time for base extension and reaction signal collection, and one round of sequencing includes one base extension.
[0053] Nucleotide refers to four natural nucleotides (such as dATP, dCTP, dGTP and dTTP or ATP, CTP, GTP and UTP) or their derivatives, and is sometimes directly represented by the bases it contains (A, T or U, C and G). A person of ordinary skill in the art can know the nucleotide or base referred to by the expression shown according to the context.
[0054] The term "nucleic acid molecule" means: a polymer form of nucleotides of any length, and may include ribonucleotides or analogs thereof, deoxyribonucleotides or analogs thereof, and mixtures formed by the above nucleotides or analogs thereof. The so-called nucleic acid molecule may refer to a single-stranded polynucleotide or a double-stranded polynucleotide. The nucleotides in the nucleic acid molecule may include naturally occurring nucleotides and functionally alternative analogs thereof. Examples of analogs can hybridize with nucleic acids in a sequence-specific manner, or can be used as a template for the replication of a specific nucleotide sequence. Naturally occurring nucleotides typically have a backbone comprising a phosphodiester bond. The analog structure may have an alternative backbone connection including any kind known in the art. Naturally occurring nucleotides typically have deoxyribose (e.g., found in DNA) or ribose (e.g., found in RNA). The analog structure may have an alternative sugar moiety, including any kind known in the art. Nucleotides may include natural bases or non-natural bases. The bases in natural DNA may include one or more of adenine, thymine, cytosine and / or guanine, and the bases of natural RNA may include one or more of adenine, uracil, cytosine and / or guanine. Nucleotides may also use any non-natural bases or base analogs, such as locked nucleic acids (LNA) and bridged nucleic acids (BNA).
[0055] The term "nucleic acid template" refers to a master nucleic acid molecule or a master nucleic acid molecule fragment that is combined with nucleotides or nucleotide analogs through multiple consecutive rounds of base extension. The so-called nucleic acid template can be the entire sequence of a nucleic acid molecule or a partial fragment of a nucleic acid molecule. The "nucleic acid template" referred to can be a nucleic acid fragment that serves as a template in an extension reaction that performs sequencing by synthesis. Since the bases added by the extension reaction satisfy the base pairing principle with the sequencing template, the sequence of the sequencing template can be determined by determining the type of bases added in each round of extension reaction. The sequence of the nucleic acid template here can generally include, but is not limited to, at least one of the sequence of the target molecule, the UMI sequence, and the sample tag sequence, and is sometimes referred to as an "insert fragment" or "target molecule" in this article.
[0056] The term "primer", also known as "probe", refers to an oligonucleotide or nucleic acid molecule that can hybridize with a target sequence of interest. In an embodiment, a primer acts as a substrate to which nucleotides can be polymerized by a polymerase. For example, a primer can be used as a starting point for DNA or RNA synthesis. For example, a sequencing primer can hybridize with a synthetic nucleic acid template strand to initiate the synthesis of a new strand complementary to the synthetic nucleic acid template strand. A primer can include any combination of nucleotides or their analogs. In some instances, a primer is a single-stranded oligonucleotide or a polynucleotide.
[0057] In the examples of the present application, it should be understood that "XX or its analogues" include "XX" and "XX analogues", illustratively: nucleotides or their analogues include nucleotides and nucleotide analogs, bases or their analogues include bases and base analogs, ribose groups or their analogues include ribose and ribose analogs, and deoxyribose groups or their analogues include deoxyribose and deoxyribose analogs.
[0058] The term "analog" or "functional analog" refers to a chemical compound that is similar in structure to another compound (the so-called "reference" compound) but differs in composition, such as the replacement of one atom by an atom of a different element, or the presence of a specific functional group, or the replacement of one functional group by another.
[0059] The term "FOV" (Field of View) refers to the field of view. During the solid substrate application process, a fixed area of the solid substrate is subjected to multiple rounds of optical imaging (photographing) using an optical camera. The area photographed by the optical camera each time can be called FOV (field of view).
[0060] The following uses sequencing by synthesis as an example to illustrate the single molecule sequencing method. The single molecule sequencing method provided in the embodiment of the present application includes:
[0061] (i) providing a solid phase support, wherein the solid phase support comprises a plurality of sites, each of which is immobilized with a nucleic acid template-primer complex.
[0062] In this step, the solid phase carrier is understood to be a carrier or support for fixing nucleic acid molecules or nucleic acid templates. In some application examples, the solid phase carrier can also be called a solid phase substrate, a sequencing chip or a sequencing biochip. In one embodiment, the solid phase carrier is a substrate with an array of micropores, and the position of each micropore corresponds to a site. Exemplarily, the solid phase carrier is a nanowell array chip, and the nanowell array chip includes an array of nanowells (nanowell) for fixing nucleic acid template-primer complexes, wherein the nanowell can be called a nanopore or micropore or hole. In the embodiment of the present application, the nanowell and nanopore referred to can be replaced with each other, and refer to a nanoscale pore structure formed on the surface of the solid phase carrier. The shape of the nanowell or nanopore is not strictly limited, and can be circular, elliptical, triangular, quadrilateral or other polygons, or even no specific shape. In some embodiments, the nanowell or nanopore is arranged in a shape with a cross section of a symmetrical figure. Exemplarily, the cross section of the nanowell or nanopore is circular or regular polygonal.
[0063] In one embodiment, the solid phase carrier is a planar substrate, and the surface of the planar substrate includes a plurality of surface-treated positions, each of which corresponds to a site for fixing the nucleic acid template-primer complex. Surface treatment refers to forming active functional groups on the surface that can be connected to the nucleic acid template-primer complex. An example of this type of solid phase carrier is a random chip.
[0064] The solid phase carrier has a plurality of sites, and there is a certain distance between two adjacent sites, and the distance is large enough to enable the optical signals generated by the optical detection labels at the adjacent sites to be distinguished.
[0065] In the present embodiment, a nucleic acid template is fixed on the surface of a solid phase carrier, and the nucleic acid template is connected to the surface of the solid phase carrier. In one embodiment, a probe is connected to the surface of the solid phase carrier, and the probe is covalently bonded to the molecule / group on the surface of the solid phase carrier, and the nucleic acid template is connected to the surface of the solid phase carrier through the probe. Wherein, the probe is an oligonucleotide or nucleic acid molecule fragment that can hybridize with a target nucleic acid molecule of interest. In one embodiment, at least a portion of the probe is configured to hybridize with at least a portion of the 3' end of the nucleic acid template. In another embodiment, one end of the nucleic acid template is covalently bonded to the molecule / group on the surface of the solid phase carrier, thereby connecting to the surface of the solid phase carrier. In the embodiment of the present application, the probe and the nucleic acid template together form a nucleic acid template-primer complex.
[0066] In this embodiment, the solid phase carrier has a plurality of sites, and the nucleic acid template is fixed on the site of the solid phase carrier accordingly. According to the embodiment of the present application, ideally, one nucleic acid template is fixed at each site. In some unavoidable cases, there may be a situation where a very small number of sites do not have a fixed nucleic acid template or one site fixes two nucleic acid templates. When the same site contains two different nucleic acid templates, the site generates two detectable signals in one round of sequencing. In order to improve the accuracy of sequencing, the sequencing signals of these sites are not counted, and the corresponding sequencing data are removed.
[0067] In some embodiments, the solid phase carrier contains a channel structure that can connect one end of the solid phase carrier to the other end. At this time, the solution and / or reagent containing the polymerization reaction in step (ii) and other solutions that need to be contacted with the solid phase carrier later can be contacted by flowing through the surface of the channel structure. In one embodiment, the channel structure on the surface of the solid phase carrier can be formed on the surface of the solid phase carrier by a method such as etching. By means such as etching, the material of a part of the surface area of the solid phase carrier is removed so that this part of the area forms a groove structure. The groove structure leads from one end of the solid phase carrier to the other end of the solid phase carrier. The channel structure on the surface of the solid phase carrier can also be formed by covering the surface of a solid phase substrate with a certain thickness with a mask material layer, and the pattern of the mask material layer corresponds to the channel structure expected to be set on the surface of the solid phase carrier. For example, the mask material layer covers the area where the corresponding groove is located, and hollows out other areas outside the groove area, and then deposits the material in the hollowed area of the mask material layer by means such as chemical deposition, thereby forming a material layer with a channel structure on the surface of the solid phase carrier, and the solid phase carrier and the material layer formed on its surface together constitute the solid phase carrier. It should be understood that the surface of the solid phase carrier may have one channel structure, or may have two or more channel structures such as 4, 8, or 16. Of course, the number of channel structures is not limited thereto. In some embodiments, the channel structure on the surface of the solid phase carrier is also called Lane.
[0068] Exemplarily, the width of the channel structure is 5 to 15 mm, and the height is 50 μm to 200 μm. It should be understood that the width and height of the solid phase carrier can be arbitrarily combined within the above range without strict restrictions. Exemplarily, when the width of the solid phase carrier is 5 to 10 mm, the height of the solid phase carrier can be in the range of 50 μm to 100 μm, or in the range of 80 μm to 120 μm, or in the range of 100 μm to 150 μm, 120 μm to 180 μm, 180 μm to 200 μm, etc.; of course, when the width of the solid phase carrier is 10 to 15 mm, similarly, the height of the solid phase carrier can be in the range of 50 μm to 100 μm, or in the range of 80 μm to 120 μm, or in the range of 100 μm to 150 μm, 120 μm to 180 μm, 180 μm to 200 μm, etc.
[0069] (ii) Four nucleotides or their analogs carrying different optical detection labels are bound to the nucleic acid template-primer complex by polymerization reaction to achieve single base extension and obtain extension products.
[0070] In this step, under conditions suitable for polymerization reaction, nucleotides or their analogs carrying different optical detection labels are added to the surface of the solid phase carrier, so that the nucleotides or their analogs are paired with the nucleic acid template through the principle of base complementary pairing and bound to the nucleic acid template-primer complex.
[0071] In some embodiments, the final concentration of each nucleotide or its analog is 125nmol / L to 1000nmol / L. It should be understood that the final concentration of nucleotides or their analogs referred to in the embodiments of the present application refers to the concentration of nucleotides or their analogs when a solution containing nucleotides or their analogs contacts a nucleic acid template-primer complex. Exemplarily, a reaction solution containing nucleotides or their analogs is introduced into a solid phase carrier, and the concentration of nucleotides or their analogs in the reaction solution is the final concentration of nucleotides or their analogs. In one embodiment, this step is performed by pumping different reagents from different kits, mixing each reagent to form a mixed solution, and flowing into the surface of the solid phase carrier. At this time, the final concentration of nucleotides or their analogs should be the concentration of nucleotides or their analogs in the mixed solution. The final concentration of nucleotides or their analogs in the embodiments of the present application is set to 125nmol / L to 1000nmol / L in order to reduce the adsorption of nucleotides or their analogs in other areas outside the surface sites of the solid phase carrier under polymerization reaction conditions, thereby reducing the non-specific adsorption formed thereby. The optical detection labels in the nucleotides or their analogs at the locations of these non-specific adsorptions are excited in step (iii) to generate optical signals, which increase the background noise in the image obtained, interfere with the recognition of the optical signals at the sites, and thus affect the accuracy of base recognition.
[0072] In the examples of the present application, the final concentration of each nucleotide or its analogue can be adjusted within the range of 125 nmol / L to 1000 nmol / L according to the type of the nucleotide or its analogue, the polymerase concentration in the reaction system, etc.
[0073] In some embodiments, the nucleotide or its analog can be represented by the general structure of Formula 1:
[0074]
[0075] In Formula 1, B is a base or an analog thereof. In some embodiments, B is cytosine or a derivative thereof, thymine or a derivative thereof, adenine or a derivative thereof, guanine or a derivative thereof, hypoxanthine or a derivative thereof, deazaadenine or a derivative thereof, deazaguanine or a derivative thereof, deazahypoxanthine or a derivative thereof, 7-methylguanine or a derivative thereof, 5,6-dihydrouracil or a derivative thereof, 5-methylcytosine or a derivative thereof, or 5-hydroxymethylcytosine or a derivative thereof.
[0076] According to an embodiment of the present invention, B is divalent cytosine or its derivatives, divalent guanine and its derivatives, dimethyl pyrimidine or its derivatives, divalent thymine or its derivatives, divalent uracil or its derivatives, divalent hypoxanthine or its derivatives, divalent xanthine or its derivatives, divalent deazaadenine or its derivatives, divalent deazaguanine or its derivatives, divalent deazahypoxanthine or its derivatives, divalent 7-methylguanine or its derivatives, divalent 5,6-dihydrouracil or its derivatives, divalent 5-methylcytosine or its derivatives, or divalent 5-hydroxymethylcytosine or its derivatives.
[0077] In formula 1, L1 is used to connect B and the cleavable azide group, L2 is used to connect the cleavable azide group and R4, and L1 and L2 are each independently a covalent bond or a covalent linking group. Wherein, the cleavable azide group is bound to one side of the nucleotide or its analog base, and by forming a certain spatial conformation, it produces a steric hindrance to the 3'hydroxyl site of ribose or deoxyribose, thereby blocking the activity of the site to undergo polymerization reaction with other nucleotides or nucleotide analogs, such as -O-CH(N3)-L2-R4. The reversible termination group can be removed (reduced to a hydroxyl group) by chemical reaction under appropriate conditions. Wherein, the appropriate conditions can be chemical reaction conditions that can induce the reversible termination group to be reduced to a hydroxyl group.
[0078] In some embodiments, L1 is an independent bond, or a substituted or unsubstituted C 1-8 Alkylene, or substituted or unsubstituted 2 to 8 membered heteroalkylene, or substituted or unsubstituted C 3-8 Cycloalkylene, or substituted or unsubstituted 3 to 8 membered isocycloalkylene, or substituted or unsubstituted C 6-8 Arylene.
[0079] Exemplarily, L1 may select the following structure:
[0080] Where g1 is an integer between 0 and 10, R L1 is NH or O; g1 is preferably 1, 4;
[0081] or Where g2 is 0, 1, 2, 3, 4 or 5, R L1 is NH or O; g2 is preferably 1, 4;
[0082] or Among them, R L1a , R L1b are independently H, -CH3, -CX3, -CHX2, -CH2X, -CN, -Ph, C 1-6 Alkyl, 2- to 6-membered alkyl or 3- to 6-membered cycloalkyl, wherein X is Cl, Br, I;
[0083] or Among them, g3 is 0, 1, 2, 3, 4, with 1 and 2 being prioritized.
[0084] In some embodiments, L2 is an independent bond, or substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkylene, or substituted or unsubstituted cycloalkyl, or substituted or unsubstituted isocycloalkyl, or substituted or unsubstituted aryl.
[0085] Exemplarily, L2 may include but is not limited to the following structure: Where R L2a , R L2b H, C 1-5 Alkyl chain, 3-6 membered cycloalkyl or phenyl, preferably H, methyl, ethyl, 5-6 membered cycloalkyl or phenyl; wherein h1, h2, h3 are each independently an integer between 0 and 6, preferably 0, 1 or 2;
[0086] or Where R L2c , R L2d are independently H or C 1-6 The alkyl chain, h4, h5, h6 are independently 0, 1, 2, 3, 4, 5 or 6, wherein h4 is preferably 0, 1 or 2, h5 is preferably 5 or 6, and h6 is preferably 4, 5 or 6.
[0087] or Among them, h7 and h8 are independently 1, 2, 3, 4, 5 or 6, preferably 1, 2 or 3.
[0088] In Formula 1, R1 is -OH or a phosphoric acid group. In the embodiments of the present application, "phosphoric acid group" refers to a phosphoric acid acyl group, that is, a group formed by removing one or two hydrogen atoms from monophosphoric acid or polyphosphoric acid, and its chemical structure is shown below, wherein n is selected from an integer from 1 to 3:
[0089]
[0090] In Formula 1, R2 is H or a chemically cleavable group. When R2 is a chemically cleavable group, it binds to the 3' hydroxyl site of ribose or deoxyribose, and can inhibit the polymerization reaction of the next nucleotide or its analog at this position, so that each polymerization reaction in step (ii) can only introduce one nucleotide or its analog on the nucleic acid chain. In addition, the chemically cleavable group can be reversibly removed by chemical reactions such as cleavage reactions under appropriate conditions to restore the 3' hydroxyl state of ribose or deoxyribose.
[0091] In some embodiments, R2 is selected from H, -CH2N3, -CH(N3)CH2F, -CH(N3)C(O)NHBu, -CH(N3)CHF2, -CH(N3)C(O)OH, -CH(N3)CH2O(CH2)6NH2, -CH(N3)CH2OArC(O)NH(CH2)6NH2, and -C(R 1a R 1b )-OC(R 2a R 2b )R7. Wherein, R6 is selected from an alkylene group having 1 to 8 carbon atoms, and exemplary, R6 is selected from -(CH2) s -or-(CH2) s -isomers, s is selected from 1-8, specifically 1, 2, 3, 4, 5, 6, 7, 8. For example, R6 can be -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6- and the like. When R2 is selected from -C(R 1a R 1b )-OC(R 2a R 2b )R7, R 1a , R 1b are each independently selected from H, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkoxy group having 1 to 6 carbon atoms, a cyano group, an optionally substituted phenyl group or an optionally substituted aralkyl group, R 2a , R 2b are each independently selected from H, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, a cyano group, or R 1a , R 2a Together with the atoms to which they are attached, they form an optionally substituted five- to eight-membered alkyl or heterocyclic group; R7 is selected from H, an optionally substituted alkenyl group having 2-6 carbon atoms, an optionally substituted cycloalkenyl group having 3-7 carbon atoms, an optionally substituted alkynyl group having 2-6 carbon atoms, and an optionally substituted silicon-containing group.
[0092] In Formula 1, R3 is H or -OR5, wherein R5 is H or a chemically cleavable group. When R5 is a chemically cleavable group, its type can refer to R2.
[0093] In Formula 1, R4 contains the optical detection label. The optical detection label refers to a group that can produce a certain detectable light signal under light excitation, wherein the light signal includes a fluorescent signal. Exemplarily, in one example, the detectable group is a fluorescent dye, in which case the nucleotide or its analog containing the fluorescent dye can produce a detectable fluorescent signal under the action of the excitation light. Exemplarily, the optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye or phytochrome.
[0094] In the structure provided by the above formula 1, when the types of nucleotides or their analogs are different, their final concentrations participating in the polymerization reaction may be different. As a first embodiment, B is selected from adenine or its analogs, and the nucleotide or its analog is an adenine nucleotide or its analog. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains adenine nucleotides or their analogs, the final concentration of adenine nucleotides or their analogs is 500nmol / L to 1000nmol / L, specifically 125nmol / L, 150nmol / L, 175nmol / L, 200nmol / L, 225nmol / L, 250nmol / L, 275nmol / L, 300nmol / L, 325nmol / L, 350nmol / L, 375nmol / L, 400nmol / L, 425nmol / L, 450nmol / L, 475nmol / L, 5nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0095] As a second embodiment, B is selected from guanine or its analogs, and the nucleotide or its analogs are guanine nucleotides or their analogs. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains guanine nucleotides or their analogs, the final concentration of guanine nucleotides or their analogs is 125 nmol / L to 500 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, 450 nmol / L, 475 nmol / L, 500 nmol / L, etc.
[0096] As a third embodiment, B is selected from cytosine or its analogs, and the nucleotide or its analogs are cytosine nucleotides or their analogs. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains cytosine nucleotides or their analogs, the final concentration of cytosine nucleotides or their analogs is 500 nmol / L to 1000 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, 450 nmol / L, 475 nmol / L, 50 ... 5nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0097] As a fourth embodiment, B is selected from thymine or its analogs, in which case the nucleotide or its analogs are thymine nucleotides or their analogs; or, when B is selected from uracil nucleotides or their analogs, in which case the nucleotide or its analogs are uracil nucleotides or their analogs. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains thymine or its analogs, or when the reaction system of the polymerization reaction in step (ii) contains uracil nucleotides or their analogs, the final concentration of the nucleotide or its analogs is 500 nmol / L to 1000 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, L, 450nmol / L, 475nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0098] In the embodiment of the present application, four nucleotides or their analogs carrying different optical detection labels are added simultaneously in step (ii) to bind to the nucleic acid template-primer complex. At this time, the optical detection labels of the nucleotides or their analogs added simultaneously are different, so that when the optical signal is detected and imaged in step (iii), different nucleotides or their analogs or their analogs bound to the nucleic acid template-primer complex can be distinguished and identified in the image or other data obtained by processing based on the image.
[0099] In this step, nucleotides or their analogs are added by solution, so that nucleotides or their analogs react uniformly with nucleic acid template-primer complex. In one implementation, a mixture solution of two nucleotides or their analogs carrying different optical detection labels is contacted with the nucleic acid template-primer complex, so that the nucleotides or their analogs are bound to the nucleic acid template-primer complex. At this time, nucleotides or their analogs, such as four nucleotides or their analogs of ATGC or AUGC, can be combined in pairs, and a group of nucleotides or their analogs can be added each time to participate in the polymerization reaction, so that the group of nucleotides or their analogs can be bound to the nucleic acid template-primer complex to complete a single base extension. Two different optical detection labels in the group of nucleotides or their analogs are used to distinguish the two nucleotides or their analogs. Afterwards, another group of nucleotides or their analogs is added to participate in the polymerization reaction, so that the group of nucleotides or their analogs is bound to the nucleic acid template-primer complex, and the second single base extension is completed, and two different optical detection labels in the group of nucleotides or their analogs are used to distinguish the two nucleotides or their analogs. So far, one round of sequencing is completed. At this point, single molecule sequencing is dual-color sequencing.
[0100] In another implementation, a mixture solution of four nucleotides or their analogs carrying different optical detection labels is contacted with the nucleic acid template-primer complex, so that the nucleotides or their analogs are bound to the nucleic acid template-primer complex. At this time, four nucleotides or their analogs, such as ATGC or AUGC, are added simultaneously to participate in the polymerization reaction, so that the four nucleotides or their analogs in the group of nucleotides or their analogs are each bound to the nucleic acid template-primer complex, completing a single base extension. At this point, a round of sequencing is completed. At this point, single molecule sequencing is four-color sequencing.
[0101] It should be understood that three nucleotides or their analogs carrying different optical detection labels can be first bound to the nucleic acid template-primer complex to achieve single base extension; and then the remaining optically detectable nucleotide or its analog can be bound to the nucleic acid template-primer complex to complete a round of sequencing.
[0102] It should be understood that different nucleotides or their analogs added at the same time carry different optical detection labels. In some embodiments, when the types of nucleotides or their analogs are different, the optical detection labels they carry are different. Exemplarily, in two-color sequencing and four-color sequencing, the nucleotide or its analog is an adenine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the Atto532; the nucleotide or its analog is a guanine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the CY5; the nucleotide or its analog is a cytosine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the IF700; the nucleotide or its analog is a thymine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the ROX. At this time, the optical detection labels of different nucleotides or their analogs are more easily identified in step (iii), especially when the single molecule sequencing is four-color sequencing, the pairing of such nucleotides and optical detection labels is conducive to improving the accuracy of base recognition.
[0103] In step (ii) of the embodiment of the present application, "binding at least two nucleotides or their analogs carrying different optical detection labels to the nucleic acid template-primer complex by polymerization reaction to achieve single base extension and obtain an extension product" is carried out under the condition of initiating a polymerization reaction between the nucleotides or their analogs and the terminal nucleotides or nucleotide analogs of the complementary chain of the nucleic acid template. That is: a polymerase is used to bind the nucleotides or their analogs carrying optical detection labels to the nucleic acid template-primer complex to achieve single base extension. The polymerase can be a DNA polymerase or an RNA polymerase, or it contains both a DNA polymerase and an RNA polymerase. In some embodiments, the polymerase is a DNA polymerase, including but not limited to one or more of 9°N enzyme, Pfu, KOD1 and MMS2.
[0104] In some embodiments, the final concentration of the polymerase is 0.005 mg / mL to 0.02 mg / mL. The final concentration of the polymerase referred to in the embodiments of the present application refers to the concentration of nucleotides or their analogs when the solution containing the polymerase contacts the solid phase carrier. Exemplarily, a reaction solution containing the polymerase is introduced into the solid phase carrier, and the concentration of the polymerase in the reaction solution is the final concentration of the nucleotides or their analogs. In one embodiment, this step is to pump different reagents from different kits, mix the reagents to form a mixed solution, and flow into the surface of the solid phase carrier. At this time, the final concentration of the polymerase should be the concentration of the polymerase in the mixed solution. The final concentration of the polymerase in the embodiment of the present application is set to 0.005 mg / mL to 0.02 mg / mL in order to reduce the adsorption of nucleotides or their analogs in other areas outside the surface site of the solid phase carrier under the conditions of the polymerization reaction, and reduce the non-specific adsorption formed thereby. The optical detection markers in the nucleotides or their analogs at the locations of these non-specific adsorptions are excited in step (iii) to generate optical signals, increase the background noise in the image obtained by imaging, interfere with the recognition of the optical signal at the site, and thus affect the accuracy of base recognition.
[0105] Exemplarily, the final concentration of the polymerase is 0.005 mg / mL, 0.006 mg / mL, 0.007 mg / mL, 0.008 mg / mL, 0.009 mg / mL, 0.01 mg / mL, 0.011 mg / mL, 0.012 mg / mL, 0.013 mg / mL, 0.014 mg / mL, 0.015 mg / mL, 0.016 mg / mL, 0.017 mg / mL, 0.018 mg / mL, 0.019 mg / mL, 0.02 mg / mL and the like.
[0106] In some embodiments, the polymerization reaction in step (ii) is carried out at a pH of 8.0 to 9.0. Thus, by regulating the concentration of the nucleotides or their analogs involved in the polymerization reaction, the concentration of the polymerase, and the pH conditions of the reaction system, the adsorption of the nucleotides or their analogs in other regions other than the solid phase carrier surface sites can be effectively reduced, the non-specific adsorption formed thereby can be reduced, the background noise in the image obtained in step (iii) can be reduced, and the accuracy of base recognition can be improved.
[0107] In the embodiment of the present application, the reaction system of the polymerization reaction in step (ii) also includes a solvent for dissolving nucleotides or their analogs and polymerase, and the solvent can be a buffer such as tris(hydroxymethylaminomethane) buffer, glycine, ethanolamine, tetraethylethylenediamine, tetramethylethylenediamine, N-butyldiethanolamine, diethylaminoethanol, Hepes buffer, or N,N-dihydroxyethylglycine.
[0108] In step (ii), four nucleotides or their analogs are bound to the nucleic acid template-primer complex by one or two single base extensions. At this time, the solid phase carrier carries an optical detection label at each site where the nucleic acid template-primer is bound.
[0109] (iii) exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image.
[0110] In this step, the optical detection marker on the surface of the solid phase carrier after the polymerization reaction is photoexcited to generate an optical signal, such as a fluorescent signal. It should be understood that different optical detection markers require different wavelengths of excitation light to generate optical signals. In some embodiments, the optical detection markers of nucleotides or their analogs added in step (ii) include at least a first optical detection marker and a second optical detection marker, and the excitation wavelengths of the first optical detection marker and the second optical detection marker differ by at least 50 nm to increase the difference in optical signals generated by the first optical detection marker and the second optical detection marker. The greater the difference in excitation wavelengths between the first optical detection marker and the second optical detection marker, the more obvious the difference in optical signals generated by the first optical detection marker and the second optical detection marker, and the easier it is for the two optical detection markers to be identified.
[0111] In this step, exciting the optical detection mark to produce an optical signal includes exposing the solid phase carrier. In some embodiments, the exposure time is 100ms to 400ms. By controlling the exposure time, the difference in optical signal intensity produced by the optical detection mark can be increased to a certain extent, which is conducive to identifying the type of nucleotides or their analogs introduced at each site and improving the accuracy of base recognition. Exemplarily, the exposure time is 100ms, 120ms, 150ms, 180ms, 200ms, 220ms, 250ms, 280ms, 300ms, 320ms, 350ms, 380ms, 400ms and the like. It should be understood that the exposure time can be adjusted according to the type of optical detection mark to achieve the purpose of increasing the difference in optical signal intensity produced by the optical detection mark. In one embodiment, the first optical detection marker is a red light-excitable fluorescent group, and the exposure time of the red light-excitable fluorescent group is 100ms to 400ms, such as 100ms, 120ms, 150ms, 180ms, 200ms, 220ms, 250ms, 280ms, 300ms, 320ms, 350ms, 380ms, and 400ms; the second optical detection marker is a green light-excitable fluorescent group, and the exposure time of the green light-excitable fluorescent group is 50ms to 100ms, such as 50ms, 60ms, 70ms, 80ms, 90ms, and 100ms.
[0112] After exciting the optical detection marker to generate an optical signal, the extension product is imaged to obtain an image. By collecting the image and analyzing the optical signal based on the image, the type of nucleotide or its analogue participating in the polymerization reaction at each site is determined, that is, the base recognition of the current round of base extension reaction is achieved.
[0113] In some embodiments, optical imaging of the solid phase carrier can be performed before step (i) to determine the background noise present on the surface of the solid phase carrier.
[0114] (iv) removing the optical detection label on the extension product.
[0115] In this step, the optical detection label on the nucleotide or its analogue bound to the end of the extension product is removed to prevent the optical detection label on the nucleotide or its analogue bound to the end of the extension product from interfering with the optical signal of the next step (iii) when steps (i)-(iii) are repeated next time.
[0116] In some embodiments, the optical detection label is connected to the nucleotide or its analog via a chemically cleavable group, and the optical detection label on the extension product is removed by using an excision reagent. Exemplarily, the chemically cleavable group on the nucleotide or its analog bound to the end of the extension product is cut off by passing an excision reagent to the surface of the solid phase carrier, thereby removing the optical detection label connected by the chemically cleavable group. Of course, it should be understood that other chemically cleavable groups on the nucleotide or its analog bound to the end of the extension product can also be cut by an excision reagent.
[0117] As an implementation scenario, the general structural formula of a nucleotide or an analog thereof is shown in Formula 1. At this time, when R2 is a chemically cleavable group, it can be reduced to H by a cleavage agent, that is, the 3' of the pentose is reduced to a hydroxyl group. The chemically cleavable group is removed by a cleavage agent, and the polymerization reaction ability of the extension product, specifically the nucleotide or an analog thereof bound to the end of the extension product, can be restored.
[0118] In some embodiments, the excision reagent includes an organic phosphine and a buffer. The organic phosphine is used as a reducing agent to reduce the chemically cleavable group, so that the chemically cleavable group falls off the extension product, and prepares for the next single base extension, and the preparation includes: on the one hand, reducing the chemically cleavable group on the pentose to a hydroxyl group, providing a reaction site for the binding of a nucleotide or its analog for the next polymerization reaction; on the other hand, reducing the azidooxymethyl group connected to one side of B, thereby removing -O-CH(N3)-L2-R4 connected to the azidooxymethyl group, and eliminating the inhibition of the group on the polymerization reaction site on the pentose.
[0119] The organic phosphine used to reduce the azidomethoxy group is selected from at least one of trivalent organic phosphine. In some embodiments, the organic phosphine is selected from at least one of tri(3-hydroxypropyl)phosphine, tri(2-carboxyethyl)phosphine, trihydroxymethylphosphine, triphenylphosphine, and tri(2-hydroxyethyl)phosphine. In some embodiments, the concentration of the organic phosphine is 10 mmol / L to 100 mmol / L, and specifically, the concentration of the organic phosphine can be 10 mmol / L, 15 mmol / L, 20 mmol / L, 25 mmol / L, 30 mmol / L, 35 mmol / L, 40 mmol / L, 45 mmol / L, 50 mmol / L, 55 mmol / L, 60 mmol / L, 65 mmol / L, 70 mmol / L, 75 mmol / L, 80 mmol / L, 85 mmol / L, 90 mmol / L, 95 mmol / L, 100 mmol / L, and the like.
[0120] In some embodiments, the buffer is selected from at least one of a primary amine buffer and a tertiary amine buffer. These buffers can be used as solvents for the reaction raw materials of the mixed reaction and can provide a stable pH environment. Compared with the primary amine buffer, the tertiary amine buffer can provide a better stable reaction environment for the reaction of reducing the azidomethoxy group to a hydroxyl group. Exemplarily, the buffer is selected from at least one of tris(hydroxymethyl)aminomethane buffer, glycine, ethanolamine, tetraethylethylenediamine, tetramethylethylenediamine, N-butyldiethanolamine, diethylaminoethanol, Hepes buffer, and N,N-dihydroxyethylglycine.
[0121] In some embodiments, the concentration of the buffer is 0.01 mol / L to 2 mol / L.
[0122] The pH environment provided when the pH value is 0.01mol / L to 2mol / L is conducive to improving the uniformity and stability of the reduction reaction. Exemplarily, the concentration of the buffer in the mixed solution is 10mmol / L, 15mmol / L, 20mmol / L, 25mmol / L, 30mmol / L, 35mmol / L, 40mmol / L, 45mmol / L, 50mmol / L, 55mmol / L, 60mmol / L, 65mmol / L, 70mmol / L, 75mmol / L, 80mmol / L, 85mmol / L, 90mmol / L, 95mmol / L, 100mmol / L, 105mmol / L, 110mmol / L, 115mmol / L, 120mmol / L, 125mmol / L, 130mmol / L, 135mmol / L, 140mmol / L, 145mmol / L, 150mmol / L, 155mmol / L, 160mmol / L, 165mmol / L, 170mmol / L, 175mmol / L, 180mmol / L, 185mmol / L, 190mmol / L, 200mmol / L, 210mmol / L, 220mmol / L, 230mmol / L, 240mmol / L, 250mmol / L, 260mmol / L, 270mmol / L, 280mmol / L, 290mmol / L, 300mmol / L, 310mmol / L, 320mmol / L, 330mmol / L, 340mmol / L, 350mmol / L, 360mmol / L, 370mmol / L, 380mmol / L, 390mmol / L mmol / L, 145mmol / L, 150mmol / L, 155mmol / L, 160mmol / L, 165mmol / L, 170mmol / L, 175mmol / L, 180mmol / L, 0.2mol / L, 0.3mol / L, 0.4mol / L, 0.5mol / L, 0.6mol / L , 0.7mol / L, 0.8mol / L, 0.9mol / L, 1.0mol / L, 1.1mol / L, 1.2mol / L, 1.3mol / L, 1.4mol / L, 1.5mol / L, 1.6mol / L, 1.7mol / L, 1.8mol / L, 1.9mol / L, 2.0mol / L and other specific situations.
[0123] In some embodiments, the optical detection label on the extension product is removed under the conditions of pH 8.0-10.5 and temperature 39°C-65°C. The pH value is 8.0-10.5 and the reaction temperature is 39°C-65°C, the structure of the nucleic acid chain is stable, and the temperature can also provide good reduction efficiency for the chemical cleavage group. Exemplarily, the reaction temperature of the excision reagent can be 39°C, 40°C, 42°C, 45°C, 48°C, 50°C, 53°C, 55°C, 57°C, 60°C, 62°C, 65°C and other specific situations. Exemplarily, the pH value of the excision reagent is 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, and the like.
[0124] The embodiment of the present application further comprises, after step (iv), a cleaning agent for cleaning to remove the excision agent to avoid residual organic phosphine. If organic phosphine remains in the steps (i)-(iii) of the current single base extension, then in the next single base extension, the organic phosphine may reduce the optical cleavage group and -O-CH(N3)- of the nucleotide or its analog, resulting in the single extension reaction not being terminated, thereby failing to effectively control the number of nucleotides or its analogs incorporated into the nucleic acid template-primer complex, resulting in prephasing (or prephase, which means that during sequencing, the nucleotides or its analogs introduced by the next or several consecutive base extensions undergo polymerization reaction in advance in the current base extension and bind to the complementary chain of the nucleic acid template), thereby failing to accurately identify the nucleic acid sequence of the introduced nucleotide region; or in the process of a new base extension reaction, before imaging the extension product after the introduction of the nucleotide or its analog, the organic phosphine has already optically cleaved the group, resulting in the optical detection label falling off, and failing to identify the type of nucleotide or its analog introduced by the single base extension reaction.
[0125] On the other hand, the connecting group selection principle of the side chain and 3'-OH. The group used in the embodiment is azide, which is a cleavable group. In practical applications, it is not limited to this group, and other cleavable blocking groups can be tried. According to the several groups shown in EP3388442A1 patent: -CH2F, -C(O)NHBu, -CHF2, -C(O)OH, -CHF2, -C6, -ArC6, these groups can be cleaved by the reducing agent tris(hydroxymethyl)phosphine. In addition, acetal can also be used as a blocking group, but this group cleavage requires the use of a palladium catalyst, and the excision reagent provided by this patent cannot effectively cleave the acetal group. The group connecting the side chain and 3'-OH can select the same group as shown in the patent, or different groups can be selected, but in the case of different groups, the selected group is required to be effectively cleaved by the same reagent at the same time, and the 3' end is in a hydroxyl state after the blocking group is cleaved.
[0126] The present invention is further described below by taking four-color sequencing as an example.
[0127] The four nucleotides used for sequencing in the embodiment of the present invention are respectively represented as: dATP-N3-Atto532, dTTP-N3-ROX, dCTP-N3-IF700 and dGTP-N3-CY5, and their general structural formulas are shown as follows:
[0128]
[0129] Wherein, B is A, T, G or C, L1 and L2 are each independently a covalent bond or a covalent linking group, R4 contains Atto532, ROX, IF700 or CY5, and n is an integer selected from 1 to 3. The excitation wavelength and emission wavelength of Atto532, ROX, IF700 or CY5 are shown in Table 1 below.
[0130] Table 1
[0131] Optical detection mark Excitation wavelength (nm) Emission wavelength (nm) Atto532 532 552 ROX 578 604 IF700 690 713 CY5 651 670
[0132] Example 1 Adsorption test of single molecule four-color sequencing
[0133] On the single-molecule sequencing platform, the nonspecific adsorption of nucleotides or their analogs on the surface of the solid phase carrier greatly interferes with the recognition of base signals during sequencing, affecting the sequencing quality. Therefore, for the nucleotides or their analogs used in the sequencing reaction, an adsorption test can be performed to determine the appropriate concentrations of the four nucleotides and polymerase during the base extension reaction.
[0134] The method of adsorption test is as follows:
[0135] Providing a surface-treated solid phase carrier, the solid phase carrier comprising a plurality of sites, each site having the ability to fix a nucleic acid template-primer complex, but not fixing the nucleic acid template-primer complex;
[0136] Prepare nucleotide solutions of dATP-N3-Atto532, dTTP-N3-ROX, dCTP-N3-IF700 and dGTP-N3-CY5 respectively, add 9°N enzyme to each nucleotide solution to form an extension reagent, name the extension reagent containing dATP-N3-Atto532 and 9°N enzyme as dATP-N3-Atto532 extension reagent, name the extension reagent containing dTTP-N3-ROX and 9°N enzyme as dTTP-N3-ROX extension reagent, name the extension reagent containing dCTP-N3-IF700 and 9°N enzyme as dCTP-N3-IF700 extension reagent, and name the extension reagent containing dGTP-N3-CY5 and 9°N enzyme as dGTP-N3-CY5 extension reagent. Set different nucleotide concentrations and 9°N enzyme concentrations in each extension reagent;
[0137] The surface of the solid phase carrier is treated with excitation light having the same excitation wavelength as the fluorescent group carried by the extension reagent to be added, and the solid phase carrier after the excitation treatment is imaged to obtain a first image; each extension reagent is added to the surface of the solid phase carrier, and the fluorescent group on each extension reagent is excited to generate an optical signal, and the solid phase carrier is imaged to obtain an image;
[0138] The image was analyzed and the average number of fluorescence signal points (adsorption points) of the image was counted. The results are shown in Table 2 below.
[0139] Table 2
[0140]
[0141]
[0142] As can be seen from Table 2, when the concentrations of dATP-N3-Atto532, dTTP-N3-ROX, and dCTP-N3-IF700 are between 500 nmol / L and 1000 nmol / L, the concentration of the nucleotide solution of dGTP-N3-CY5 is between 125 nmol / L and 500 nmol / L, and the concentration of 9°N is 0.01 mg / mL, the number of adsorption points is less than 500. The adsorption ratio on the surface of the solid phase carrier is calculated by (number of adsorption points / total number of sites on the carrier surface) × 100%. An adsorption ratio within 2% is beneficial to improving the accuracy of base recognition and ultimately improving sequencing quality.
[0143] Example 2 Single molecule four-color sequencing
[0144] The method of single-molecule four-color sequencing is as follows:
[0145] Providing a surface-treated solid phase carrier, the solid phase carrier comprising a plurality of sites, each site having a fixed nucleic acid template-primer complex;
[0146] Prepare a nucleotide solution of 500 nmol / L dATP-N3-Atto532, 500 nmol / L dTTP-N3-ROX, 1000 nmol / L dCTP-N3-IF700 and 125 nmol / L dGTP-N3-CY5, add 9°N enzyme to a concentration of 0.01 mg / mL to form an extension reagent; the extension reagent containing dTTP-N3-ROX and 9°N enzyme is named dTTP-N3-ROX extension reagent, the extension reagent containing dCTP-N3-IF700 and 9°N enzyme is named dCT P-N3-IF700 extension reagent, and the extension reagent containing dGTP-N3-CY5 and 9°N enzyme is named dGTP-N3-CY5 extension reagent. Set different nucleotide concentrations and 9°N enzyme concentrations in each extension reagent;
[0147] An extension reagent is added to the surface of the solid phase carrier, and the solid phase carrier surface is irradiated with 532nm laser and 640nm laser excitation light to excite the fluorescent group on the extension reagent to generate an optical signal, and the solid phase carrier is imaged and an image is collected.
[0148] Due to the limitations of image clarity and single molecules, it is difficult for multi-color sequencing to distinguish different types of nucleotide images, especially GC images. In this example, for a 640nm laser, four exposure times of 50ms, 100ms, 200ms and 400ms were set to observe the brightness difference between dCTP-N3-IF700 and dGTP-N3-CY5. The results are as follows: Figure 1 As shown in the figure, when the exposure time is 50ms, the fluorescence intensity of dCTP-N3-IF700 and dGTP-N3-CY5 is close; as the exposure time increases, the difference in fluorescence intensity between dCTP-N3-IF700 and dGTP-N3-CY5 increases. For a 640nm laser, when the exposure time is above 100ms, GC can be better distinguished on the image. By increasing the exposure time, the difference in fluorescence brightness of multiple nucleotides such as GC in the same fluorescence channel in multi-color sequencing can be increased. Specifically, Figure 2 As shown, under the exposure time of 50ms with 640nm laser, the fluorescence image formed by dCTP-N3-IF700 participating in the reaction alone (in single-color sequencing) is as follows Figure 2 As shown in the left figure, the GC fluorescence image collected after adding four nucleotides at the same time is as follows Figure 2 As shown in the right figure, it can be seen that after G is strung to C, it is difficult to distinguish the GC point by brightness in C. In this embodiment, the exposure time is adjusted, such as adjusting the exposure time of the red light excitation group to 100ms-400ms and the exposure time of the green light excitation group to 50ms-100ms, to distinguish the images that are difficult for the algorithm to distinguish.
[0149] 532nm and 640nm lasers were used to verify different exposure times for 40-cycle base extension. The effects of four different exposure conditions on the 40-cycle read length distribution were analyzed: 532nm exposure 80ms & 640nm exposure 400ms, 532nm exposure 100ms & 640nm exposure 400ms, 532nm exposure 80ms & 640nm exposure 200ms, and 532nm exposure 60ms & 640nm exposure 200ms. The results are as follows: Figure 3 As shown. Figure 3 It can be seen that the exposure time has an impact on the sequencing read length. Specifically, as the exposure time increases, the light damage increases, resulting in a shorter read length. Therefore, on the basis that the algorithm can distinguish, a shorter exposure time is selected.
[0150] The 532 laser was used to set the exposure time to 80ms, and the 640nm laser was used to expose for 150ms and 200ms respectively for 50-cycle base extension. The sequencing data is shown in Table 3 below (the number of reads uniquely aligned to the genome refers to the number of reads uniquely aligned to the reference genome within a field of view, i.e., the central 1024×1024 pixel area of a FOV), where error rate = mismatch rate + deletion error rate + insertion error rate. It can be seen that the sequencing data obtained by performing 50-cycle base extension at exposure times of 150ms and 200ms is not much different; the results of the 50-cycle read length distribution at different exposure times are shown in Table 3 below. Figure 4 As shown, there is no significant difference in the read length distribution between exposures of 150ms and 200ms. Combined with the long sequencing results, when the 532 laser is 80ms and the 640 laser is 150ms, dCTP-N3-IF700 and dGTP-N3-CY5 can be distinguished from each other in terms of brightness, and the read length has little effect. Finally, the main peak of the 50cycle sequencing read length distribution is around 50bp, and the error rate is 7% to 8%, which can achieve four-color sequencing on a single-molecule sequencing platform. Therefore, based on the consideration of saving sequencing time, the subsequent 640nm laser can consider using an exposure time of 150ms.
[0151] Table 3
[0152]
[0153] Example 3 Single molecule four-color sequencing
[0154] The method of single-molecule four-color sequencing is as follows:
[0155] Providing a surface-treated solid phase carrier, the solid phase carrier comprising a plurality of sites, each site having a fixed nucleic acid template-primer complex;
[0156] A nucleotide solution with a concentration of 500 nmol / L dATP-N3-Atto532, a concentration of 500 nmol / L dTTP-N3-ROX, a concentration of 1000 nmol / L dCTP-N3-IF700 and a concentration of 125 nmol / L dGTP-N3-CY5 was prepared, and 9°N enzyme was added to a concentration of 0.01 mg / mL to form an extension reagent. The extension reagent containing dATP-N3-Atto532 and 9°N enzyme was named dATP-N3-Atto532 extension reagent, the extension reagent containing dTTP-N3-ROX and 9°N enzyme was named dTTP-N3-ROX extension reagent, the extension reagent containing dCTP-N3-IF700 and 9°N enzyme was named dCTP-N3-IF700 extension reagent, and the extension reagent containing dGTP-N3-CY5 and 9°N enzyme was named dGTP-N3-CY5 extension reagent. Different nucleotide concentrations and 9°N enzyme concentrations were set in each extension reagent;
[0157] An extension reagent is added to the surface of the solid phase carrier, and the 532 laser and 640 laser excitation light are used to irradiate the surface of the solid phase carrier and excite the fluorescent group on the extension reagent to generate an optical signal, and the solid phase carrier is imaged and an image is collected.
[0158] A Tris buffer system containing THPP is prepared as an excision reagent, and various excision reagents are added to the surface of a solid phase carrier to perform an excision reaction on the azidomethoxy group. The excision percentage of the azidomethoxy group on the surface of the solid phase carrier is calculated (the optical signal points before and after the excision are calculated, and the excision percentage of the azidomethoxy group = (the number of optical signal points before the excision - the number of optical signal points after the excision) / the number of optical signal points before the excision × 100%), or the residual percentage of the azidomethoxy group on the surface of the solid phase carrier is calculated (the optical signal points before and after the excision are calculated, and the residual percentage of the azidomethoxy group = the number of optical signal points after the excision / the number of optical signal points before the excision × 100%).
[0159] (1) In the excision reagent, the concentration of Tris was 2.0 mol / L, and THPP was set to four concentrations: 10 mmol / L, 25 mmmol / L, 50 mmol / L, and 100 mmol / L. The optical signal statistics before and after the excision reaction under the four concentration conditions are as follows: Figure 5 As shown, it was calculated that the removal percentages under the four concentration conditions were 67.79%, 63.92%, 68.87% and 68.67%, respectively. It can be seen that increasing the THPP concentration has no obvious effect on improving the removal efficiency.
[0160] (2) In the excision reagent, the concentration of THPP was 10.0 mmol / L, and the Tris buffer was set to four concentrations: 0.01 mol / L, 0.2 mol / L, 1 mol / L, and 2 mol / L. The optical signal statistics before and after the excision reaction under the four concentration conditions are as follows: Figure 6 shown. Figure 6 The results show that the residual percentages after the excision reaction under the four concentration conditions are 32.66%, 3.46%, 1.93%, and 0.48%, respectively. It can be seen that the concentration of Tris buffer affects the removal of azidomethoxy groups, thereby affecting the sequencing error rate. When the concentration of Tris buffer is 0.2 mol / L to 2.0 mol / L, the residual percentage of azidomethoxy groups is lower.
[0161] (3) In the excision reagent, under the conditions of Tris concentration of 2.0 mol / L, THPP concentration of 10.0 mmol / L, and pH set to 8.0, 9.0, and 10.3, the optical signal statistics before and after the excision reaction under the three pH conditions are as follows: Figure 7 shown. Figure 7 The results show that the residual percentages after the excision reaction under the three pH conditions were 13.93%, 2.95%, and 1.50%, respectively. It can be seen that pH affects the removal of azidomethoxy groups, thereby affecting the sequencing error rate. When the pH is 9 or above, the azidomethoxy group has a lower residual percentage. Considering that too high pH affects the stability of nucleic acid molecules, the pH value of 9 to 10.3 is appropriate for four-color sequencing.
[0162] (4) In the step of excision reaction of the azidomethoxy group, a Tris concentration of 2.0 mol / L, a THPP concentration of 10.0 mmol / L, and a pH value of 9.0 were used as excision reagents. The excision reactions were carried out at temperatures of 39° C., 57° C., 61° C., and 65° C., respectively. The optical signal statistics before and after the excision reactions under the four temperature conditions are as follows: Figure 8 shown. Figure 7 The results show that the residual percentages after excision reaction under the four temperature conditions are 15.79%, 4.50%, 2.71%, and 2.64%, respectively. It can be seen that temperature affects the removal of azidomethoxy groups, thereby affecting the sequencing error rate. When the temperature is 39°C or above, the azidomethoxy group has a lower residual percentage. Considering that high temperature affects the stability of nucleic acid molecules, the temperature for four-color sequencing is preferably 39°C to 65°C.
[0163] The excision reagent was optimized through THPP concentration gradient, Tris concentration gradient, pH gradient and temperature gradient. Among them, the increase of Tris concentration can significantly reduce the residue after excision. Under the condition of 2 mol / L high concentration Tris, the increase of pH and temperature is also conducive to further reducing the residue after excision. The final THPP excision efficiency is above 95%.
[0164] Example 4 Single molecule four-color sequencing
[0165] The method includes:
[0166] (1) providing a surface-treated solid phase carrier, wherein the solid phase carrier comprises a plurality of sites, each of which has a fixed nucleic acid template-primer complex;
[0167] (2) Prepare a nucleotide solution of 500 nmol / L dATP-N3-Atto532, 500 nmol / L dTTP-N3-ROX, 1000 nmol / L dCTP-N3-IF700, and 125 nmol / L dGTP-N3-CY5 (buffer: 50 mmol / L Tris-Base pH 8.8, 50 mmol / L NaCl, 10 mmol / L (NH4)2S04, 3 mmol / L MgSO4), and add 9°N enzyme to a concentration of 0.01 mg / mL to form an extension reagent;
[0168] (3) adding an extension reagent to the surface of the solid phase carrier, irradiating the surface of the solid phase carrier with 532 laser and 640 laser excitation light for 80 m and 150 ms respectively, imaging the solid phase carrier, and collecting images;
[0169] (4) Prepare an excision reagent containing the following ingredients: 2 mol / L Tris-Base, 1 mol / L sodium chloride, 10 mmol / L THPP, 0.05% Tween 20, pH 9.0, add the excision reagent to the surface of the solid phase carrier, and perform an excision reaction on the azidomethoxy group.
[0170] Repeat the above steps (1)-(4) 50 times, that is, sequence 50 cycles. The read length distribution of 50 cycles is as follows: Fig. 9 As shown in the figure, it can be seen that the main peak of the 50-cycle sequencing read length distribution is around 50bp, and the proportion of sequencing terminated before 45 cycles is relatively small.
[0171] The error rate of 50 cycles was calculated and the results are described in Table 4 below, where the number of Reads uniquely aligned to the genome refers to the number of Reads uniquely aligned to the reference genome within a 1024×1024 pixel area in the center of a field of view, i.e., a FOV, and the error rate (error rate = mismatch rate + deletion error rate + insertion error rate) is about 6%.
[0172] Table 4
[0173]
[0174] The statistical results of error types in four-color sequencing are as follows Fig.10 As shown, Ins_N indicates an error of insertion type N, Del_N indicates an error of deletion type N, N1->N2 indicates that N1 is mistakenly identified as an error type of N2, and N, N1, and N2 all represent one of A, T, G, and C. Fig.10 It can be seen that the error types and their distribution ratios of 50 cycles of four-color sequencing are within the acceptable range of single-molecule sequencing.
[0175] The reaction efficiency was high when the dG-Atto647N base was substituted for the dG-CY5 base. The error rate statistics are shown in Table 4. The error rate after dG-Atto647N substitution was similar, but the flux was slightly higher, so it can be used as a substitute for dG-CY5.
[0176] In summary, four-color sequencing can be achieved on a single-molecule platform with good accuracy and long read length.
[0177] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A single molecule sequencing method, characterized in that: The steps include: (i) providing a solid phase carrier, wherein the solid phase carrier comprises a plurality of sites, each of which is fixed with a nucleic acid template-primer complex; (ii) binding four nucleotides or their analogs carrying different optical detection labels to the nucleic acid template-primer complex through a polymerization reaction to achieve single base extension and obtain an extension product; (iii) exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image; (iv) removing the optical detection label on the extension product; (v) replacing the nucleic acid template-primer complex with the extension product from which the optically detectable label has been cleaved, and repeating the above steps (ii) to (iv) one or more times to determine the template nucleic acid sequence.
2. The sequencing method according to claim 1, characterized in that In step (ii), a mixture solution of two or four nucleotides or their analogs carrying different optical detection labels is contacted with the nucleic acid template-primer complex to allow the nucleotides or their analogs to bind to the nucleic acid template-primer complex.
3. The sequencing method according to claim 2, characterized in that In step (ii), the final concentrations of the four nucleotides or their analogs are 125 nmol / L to 1000 nmol / L, respectively.
4. The sequencing method according to any one of claims 1 to 3, characterized in that The general formula of the nucleotide or its analogue is shown in Formula 1: Wherein, B is a base or an analog thereof, L1 and L2 are each independently a covalent bond or a covalent linking group, R1 is -OH or a phosphate group, R2 is H or a chemically cleavable group, R3 is H or -OR5, R5 is H or a chemically cleavable group, and R4 contains the optical detection label; Optionally, B is selected from adenine or its analogs, guanine or its analogs, cytosine or its analogs, thymine or its analogs or uracil or its analogs; Optionally, in step (ii), B is selected from adenine or its analogues, cytosine or its analogues, thymine or its analogues or uracil or its analogues, and the final concentration of each nucleotide or its analogue is 500nmol / L to 1000nmol / L; B is guanine or its analogues, and the final concentration of the nucleotide or its analogue is 125nmol / L to 500nmol / L.
5. The sequencing method according to any one of claims 1 to 4, characterized in that: Different nucleotides or their analogs carry different optical detection labels; Optionally, the optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye or phycoerythrin; Optionally, the nucleotide or its analogue is an adenine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the Atto532; the nucleotide or its analogue is a guanine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the CY5; the nucleotide or its analogue is a cytosine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the IF700; the nucleotide or its analogue is a thymine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the ROX.
6. The sequencing method according to any one of claims 1 to 5, characterized in that: In step (ii), four nucleotides or their analogs carrying optical detection labels are bound to the nucleic acid template-primer complex by a polymerase to achieve single base extension; wherein the polymerase is a DNA polymerase and / or an RNA polymerase, and the final concentration of the polymerase is 0.005 mg / mL to 0.02 mg / mL; Optionally, the polymerase includes one or more of 9°N enzyme, Pfu, KOD1 and MMS2.
7. The sequencing method according to any one of claims 1 to 6, characterized in that: In step (ii), the polymerization reaction is carried out at a pH of 8.0 to 9.
0.
8. The sequencing method according to any one of claims 1 to 7, characterized in that: The optical detection label is connected to the nucleotide or its analog via a chemically cleavable group, and in step (iv), the removal of the optical detection label on the extension product is achieved by using an excision reagent, and the excision reagent includes an organic phosphine and a buffer; Optionally, removing the optical detection label on the extension product is performed at a pH value of 8.0 to 10.5 and a temperature of 39° C. to 65° C.; Optionally, the concentration of the organic phosphine is 10 mmol / L to 100 mmol / L; and / or the concentration of the buffer is 0.01 mol / L to 2.0 mol / L; Optionally, the organic phosphine is selected from tris(3-hydroxypropyl)phosphine, tris(2-carboxyethyl)phosphine, trishydroxymethylphosphine, triphenylphosphine, tris(2-hydroxyethyl)phosphine.
9. The sequencing method according to any one of claims 1 to 8, characterized in that: In step (iii), exciting the optical detection label to generate an optical signal comprises exposing the solid phase carrier to light, wherein the exposure time is 100 ms to 400 ms.
10. The sequencing method according to any one of claims 1 to 9, characterized in that: The optical detection mark comprises a first optical detection mark and a second optical detection mark, and the excitation wavelengths of the first optical detection mark and the second optical detection mark differ by at least 50 nm; Optionally, the first optical detection marker is a red light excitable fluorescent group, and the exposure time of the red light excitable group is 100ms to 400ms; the second optical detection marker is a green light excitable fluorescent group, and the exposure time of the green light excitable group is 50ms to 100ms.
Citation Information
Patent Citations
Modified nucleosides or nucleotides
EP3388442A1
